More is being done than ever before to monetise neglected pharma IP
Roivant’s most recent spinout shows that it is still on the hunt for deprioritised life sciences patents
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.